BioPred

More Details

BioPred develops engineered Bdellovibrio bacteriovorus bacteria as a biotechnological solution to fight antimicrobial-resistant infections. The company aims to provide alternative treatments to antibiotics, reducing the global threat of superbugs.

Business Model

BioPred will operate on a B2B business model, partnering with hospitals and healthcare institutions to provide its engineered Bdellovibrio bacteriovorus bacteria as a treatment option. The company will also collaborate with pharmaceutical companies to incorporate their bacteria in combination therapies.

Unique Selling Proposition

BioPred offers a biotechnological alternative to antibiotics, using engineered predatory bacteria to target and destroy antibiotic-resistant pathogens, significantly mitigating the threat posed by superbugs.

Minimum Viable Product

The MVP for BioPred will consist of a prototype of the engineered Bdellovibrio bacteriovorus bacteria, initial in-vitro testing results, and partnership agreements with one or two healthcare institutions for clinical trials.

Features List

Marketing Ideas

Target Market

Subscribe now to view target market

Detailed Business Plan

Subscribe now to view detailed business plan

Competitors

Subscribe now to view competitors